Biopharmaceutical research companies have conducted nearly 500 clinical trials of new medicines in Worcester over the past 14 years, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Eighty-four of the more than 700 trials added throughout Massachusetts since 2012 have taken place in Worcester, the report found. Nearly 40 of the current Worcester trials target chronic diseases such as cancer, heart disease, stroke and diabetes.
“Clinical research in Central Massachusetts allows our researchers to be involved in the development of important new medicines for patients,” said Tim Murray, president of the Worcester Regional Chamber of Commerce, in a statement. “Clinical trials have benefited such institutions as the UMass Medical School, Reliant Medical Group at Worcester Medical Center and Saint Vincent Hospital.”
UMass Medical School, Reliant and the Fallon Clinic at Worcester Medical Center are playing host to many of the 29 cancer-related trials taking place in the Worcester area, the report found. UMass Medical School is also conducting clinical trials for heart disease and stroke, the report found.
